Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, October 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 5 patents that reference this research output.

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity, including 1 additional patents.